IDOGEN Stock Overview
Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs, and the body’s own cells or tissues in Sweden.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr0.30|
|52 Week High||kr3.80|
|52 Week Low||kr0.27|
|1 Month Change||-24.24%|
|3 Month Change||-50.98%|
|1 Year Change||-91.98%|
|3 Year Change||-98.21%|
|5 Year Change||-99.48%|
|Change since IPO||-99.56%|
Recent News & Updates
|IDOGEN||SE Biotechs||SE Market|
Return vs Industry: IDOGEN underperformed the Swedish Biotechs industry which returned -20.4% over the past year.
Return vs Market: IDOGEN underperformed the Swedish Market which returned -23.6% over the past year.
|IDOGEN Average Weekly Movement||9.1%|
|Biotechs Industry Average Movement||8.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in SE Market||12.2%|
|10% least volatile stocks in SE Market||4.7%|
Stable Share Price: IDOGEN is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: IDOGEN's weekly volatility (9%) has been stable over the past year.
About the Company
Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs, and the body’s own cells or tissues in Sweden. The company’s advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection primarily kidney transplantation; and IDO AID for the treatment of autoimmune diseases.
Idogen Fundamentals Summary
|IDOGEN fundamental statistics|
Is IDOGEN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IDOGEN income statement (TTM)|
|Cost of Revenue||kr0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 25, 2022
|Earnings per share (EPS)||-0.54|
|Net Profit Margin||-318.85%|
How did IDOGEN perform over the long term?See historical performance and comparison
Is IDOGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IDOGEN?
Other financial metrics that can be useful for relative valuation.
|What is IDOGEN's n/a Ratio?|
Price to Sales Ratio vs Peers
How does IDOGEN's PS Ratio compare to its peers?
|IDOGEN PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
Price-To-Sales vs Peers: IDOGEN is good value based on its Price-To-Sales Ratio (1.8x) compared to the peer average (7.3x).
Price to Earnings Ratio vs Industry
How does IDOGEN's PE Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Sales vs Industry: IDOGEN is good value based on its Price-To-Sales Ratio (1.8x) compared to the Swedish Biotechs industry average (19.1x)
Price to Sales Ratio vs Fair Ratio
What is IDOGEN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1.8x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate IDOGEN's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of IDOGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IDOGEN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IDOGEN's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IDOGEN's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Idogen forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Idogen has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has Idogen performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IDOGEN is currently unprofitable.
Growing Profit Margin: IDOGEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IDOGEN is unprofitable, and losses have increased over the past 5 years at a rate of 13.1% per year.
Accelerating Growth: Unable to compare IDOGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IDOGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.4%).
Return on Equity
High ROE: IDOGEN has a negative Return on Equity (-94.18%), as it is currently unprofitable.
Discover strong past performing companies
How is Idogen's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: IDOGEN's short term assets (SEK45.1M) exceed its short term liabilities (SEK4.6M).
Long Term Liabilities: IDOGEN's short term assets (SEK45.1M) do not cover its long term liabilities (SEK-1,000.0).
Debt to Equity History and Analysis
Debt Level: IDOGEN is debt free.
Reducing Debt: IDOGEN has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IDOGEN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IDOGEN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 20.8% each year
Discover healthy companies
What is Idogen current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IDOGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IDOGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IDOGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IDOGEN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IDOGEN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Anders Karlsson (57 yo)
Mr. Anders Karlsson, M.B.A., has been Chief Executive Officer and Managing Director of Idogen AB (publ) since August 19, 2019. Mr. Karlsson served as the Chairman of the Board and Chief Executive Officer o...
CEO Compensation Analysis
Compensation vs Market: Anders's total compensation ($USD268.11K) is about average for companies of similar size in the Swedish market ($USD233.45K).
Compensation vs Earnings: Anders's compensation has increased whilst the company is unprofitable.
Experienced Management: IDOGEN's management team is considered experienced (2.8 years average tenure).
Experienced Board: IDOGEN's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 297.4%.
Idogen AB (publ)'s employee growth, exchange listings and data sources
- Name: Idogen AB (publ)
- Ticker: IDOGEN
- Exchange: OM
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr21.752m
- Shares outstanding: 72.51m
- Website: https://www.idogen.com
Number of Employees
- Idogen AB (publ)
- Medicon Village
- ScheelevAegen 2
- Skåne County
- 223 81
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.